Assessing the IMpact of Alopecia Areata (AA) on PatIents’ and CaregiverS’ in Australia (MARISSA)

Not Applicable

Completed

Conditions: Alopecia Areata
Inflammatory and Immune System - Autoimmune diseases

Registration Number: ACTRN12623000158662

Lead Sponsor: Pfizer Australia Pty Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 428

Inclusion Criteria

Patient survey
•Self-reported medically confirmed diagnosis of AA for at least 3 months before the survey completion date (assessed via online screener)
•For adolescents aged 12-17 years old, consent from parents/guardians and assent from the patients (assent form 12-14 years and 15-17 years) will be required, this will be obtained sequentially).

Caregiver survey
•Parent or legal guardian of a patient aged 12-17 years with self-reported medically confirmed diagnosis of AA for at least 3 months before the survey completion date

Exclusion Criteria

Patients with a medical diagnosis of any form of cancer in the past 5 years or with a medical diagnosis of androgenetic alopecia (AGA) and patient or dependant with a self-reported medically confirmed diagnosis of AA for less than 3 months before the survey completion date
Adolescents can only participate if caregiver has provided contact details on adolescent behalf

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of Alopecia Areata among patients assessed using Scalp Hair Assessment PRO™ validated instrument.<br><br><br><br><br>[ Point in time for participants recruited over 8 weeks];Impact of Alopecia Areata among patients assessed using AAPPO validated instrument<br>[ Point in time for participants recruited over 8 weeks];Symptoms of Alopecia Areata among adult patients assessed using AAPPO validated instrument.<br>[ Point in time for participants recruited over 8 weeks]

Secondary Outcome Measures

Name	Time	Method
Describe socio-demographic and clinical characteristics of patients with AA assessed using socio-demographic characteristic bespoke survey developed for the study.[ Point in time for participants recruited over 8 weeks];Describe socio-demographic and clinical characteristics of caregivers of adolescents 12 to 17 years of age with AA assessed using socio-demographic characteristic bespoke survey developed for the study.[ Point in time for participants recruited over 8 weeks];PRIMARY OUTCOME<br>Depression and anxiety among Alopecia Areata patients assessed using HADS validated instrument.[ Point in time for participants recruited over 8 weeks];PRIMARY OUTCOME<br>Productivity Alopecia Areata patients assessed using WPAI+CIQ validated instrument.[ Point in time for participants recruited over 8 weeks];PRIMARY OUTCOME<br>Impact of dependent's Alopecia Areata on parental perception of health outcomes using QLCCDQ validated instrument.<br>[ Point in time for participants recruited over 8 weeks.]